Aerodigestive adverse effects during intravenous pentamidine infusion for Pneumocystis jirovecii pneumonia prophylaxis.
Adolescent
Adult
Antifungal Agents
/ administration & dosage
Antineoplastic Combined Chemotherapy Protocols
/ adverse effects
Child
Child, Preschool
Combined Modality Therapy
Drug-Related Side Effects and Adverse Reactions
/ epidemiology
Female
Follow-Up Studies
Hematopoietic Stem Cell Transplantation
/ adverse effects
Humans
Infusions, Intravenous
Leukemia
/ pathology
Male
Michigan
/ epidemiology
Pentamidine
/ administration & dosage
Pneumocystis carinii
/ drug effects
Pneumonia, Pneumocystis
/ drug therapy
Prognosis
Self Report
Surveys and Questionnaires
Upper Gastrointestinal Tract
/ drug effects
Young Adult
adverse reactions
aero-digestive
children
intravenous
pentamidine
Journal
Pediatric blood & cancer
ISSN: 1545-5017
Titre abrégé: Pediatr Blood Cancer
Pays: United States
ID NLM: 101186624
Informations de publication
Date de publication:
01 2021
01 2021
Historique:
received:
23
06
2020
revised:
04
09
2020
accepted:
06
09
2020
pubmed:
27
9
2020
medline:
28
4
2021
entrez:
26
9
2020
Statut:
ppublish
Résumé
Aerodigestive adverse effects (AD-AE) during intravenous pentamidine (IV-P) infusion for Pneumocystis jiroveci pneumonia prophylaxis are uncommon in retrospective chart review studies. We conducted a survey in patients on IV-P, which included 31 specific questions. Twenty-five patients were included in the analysis; AD-AE were observed in 22 (88%) with recurrence of symptoms in 88% participants with subsequent infusions. Five leading symptoms were congestion (48%), lip tingling (32%), nausea (28%), tongue tingling (24%), vomiting, and throat swelling (17%); multiple symptoms were reported in 72% of the patients. In conclusion, AD-AE of IV-P infusion are common, self-limited, and tend to be recurrent.
Substances chimiques
Antifungal Agents
0
Pentamidine
673LC5J4LQ
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e28714Informations de copyright
© 2020 Wiley Periodicals LLC.
Références
Quinn M, Fannin JT, Sciasci J, et al. Pentamidine for prophylaxis against Pneumocystis jirovecii pneumonia in pediatric oncology patients receiving immunosuppressive chemotherapy. Antimicrob Agents Chemother. 2018;62:e00173-18.
Kruizinga MD, Bresters D, Smiers FJ, Lankester AC, Bredius RGM. The use of intravenous pentamidine for the prophylaxis of Pneumocystis pneumonia in pediatric patients. Pediatr Blood Cancer. 2017;64. https://doi.org/10.1002/pbc.26453
Levy ER, Musick L, Zinter MS, et al. Safe and effective prophylaxis with bimonthly intravenous pentamidine in the pediatric hematopoietic stem cell transplant population. Pediatr Infect Dis J. 2016;35:135-141.
Clark A, Hemmelgarn T, Danziger-Isakov L, Teusink A. Intravenous pentamidine for Pneumocystis carinii/jiroveci pneumonia prophylaxis in pediatric transplant patients. Pediatr Transplant. 2015;19:326-331.
Liu Y, Smith CA, Panetta JC, et alAntibodies predict pegaspargase allergic reactions and failure of rechallenge. J Clin Oncol. 2019;37:2051-2061.
Kalambay J, Ghazanfar H, Martes Pena KA, Munshi RA, Zhang G, Patel JY. Pathogenesis of drug induced non-allergic angioedema: a review of unusual etiologies. Cureus. 2017;9:e1598.
Kosirog-Glowacki JL, Bressler LR. Cyclophosphamide-induced facial discomfort. Ann Pharmacother. 1994;28:197-199.
Settipane RA, Kaliner MA. Chapter 14: nonallergic rhinitis. Am J Rhinol Allergy. 2013;27(Suppl 1):S48-S51.